Table 2.
Comparison of anti-SARS-CoV IgG titres among different patient groups
| Patient groups | All cases [median IgG titre (IQR)] | p-Value (Mann–Whitney) | CS-treated [median IgG titre (IQR)] | p-Value (Mann–Whitney) |
|---|---|---|---|---|
| Male | 640 (320, 640) | 0.286 | 640 (320, 640) | 0.386 |
| Female | 320 (160, 640) | 320 (320, 640) | ||
| Age <65 years | 320 (200, 640) | 0.332 | 320 (320, 640) | 0.347 |
| Age ≥65 years | 640 (320, 640) | 640 (320, 640) | ||
| ICU care | 640 (640, 640) | 0.001* | 640 (640, 640) | 0.002* |
| No ICU care | 320 (160, 640) | 320 (320, 640) | ||
| O2-therapy | 640 (320, 640) | 0.002* | 640 (320, 640) | 0.008* |
| No O2-therapy | 320 (160, 640) | 320 (320, 640) | ||
| CS-treated | 640 (320, 640) | 0.088 | ||
| Not CS-treated | 320 (160, 640) | |||
| Positive RT-PCR (all)a | 320 (160, 640) | 0.325 | 320 (160, 640) | 0.714 |
| Negative RT-PCR (all)a | 640 (320, 640) | 640 (320, 640) | ||
| Positive RT-PCR (fecal)a | 160 (40, 560) | 0.004* | 160 (160, 640) | 0.060 |
| Negative RT-PCR (fecal)a | 480 (320, 640) | 640 (320, 640) | ||
| Initial lymphocyte <1.0 | 640 (320, 640) | 0.058 | 640 (320, 640) | 0.028* |
| Initial lymphocyte ≥1.0 | 320 (160, 640) | 320 (240, 640) | ||
| Lymphocyte nadir <0.5 | 640 (320, 640) | 0.740 | 640 (320, 640) | 0.754 |
| Lymphocyte nadir ≥0.5 | 320 (320, 640) | 640 (320, 640) |
ICU: intensive care unit; O2-therpay: oxygen supplement required to maintain oxygen saturation >95%; CS: intravenous high-dose corticosteroid (methylprednisolone).
a
“all”: on respiratory and fecal specimens; “fecal”: on fecal specimens collected upon discharge at ≥21 days; included only respiratory specimen RT-PCR negative cases.
*
Statistically significant.